Kyle T. Baron, Pharm.D., Ph.D.

Principal Scientist I

Kyle joined Metrum in 2010 after receiving his Pharm.D. and Ph.D. in  Experimental and Clinical Pharmacology from the University of Minnesota. As a member of our translational and systems pharmacology group, Kyle has worked to support sponsor development programs in a variety of therapeutic areas, including chronic hepatitis C infection, HIV, calcium homeostasis and bone health, type-2 diabetes, and cystic fibrosis.  

Kyle is the developer and maintainer of mrgsolve ( and also leads workshops at all levels to guide other M&S scientists in the effective use of this simulation tool in PKPD, PBPK, and QSP modeling. Kyle also serves as adjunct faculty in Experimental and Clinical Pharmacology at the University of Minnesota.  

Recent publications by this scientist

Population pharmacokinetics and exposure-response (efficacy and safety/tolerability) of empagliflozin in patients with type 2 diabetes

September 1, 2016

Baron KT, Macha S, Broedl UC, Nock V, Retlich S, Riggs M.  Diabetes Ther. 2016 Sep;7(3):455-71.

Download PDF

Comparing the performance of four open-source methods for multiple parameter estimation in a systems pharmacology model

June 1, 2016

Eudy RJ, Riggs MM, Baron K.  Presented at the Sanofi–MSISB Mount Sinai Systems Pharmacology Symposium, June 2016.

Download PDF

Simulation from ODE-based population PK/PD and systems pharmacology models in R with mrgsolve

October 1, 2015

Baron KT and Gastonguay MR.  Presented at the 6th American Conference on Pharmacometrics (ACoP), Arlington, VA; October 2015.

Download PDF